Hormonal therapies are effective for recurrent and advanced prostate cancer, with PSA levels crucial for risk stratification. Combination hormone therapy is advised for metastatic prostate cancer, ...
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results